LAKEWOOD-AMEDEX BIOTHERAPEUT
LABTNASDAQ🏆 #3836 by market capUS Equity
$893.19▼ $16.26 (−1.82%)
Simulated price1h—
24h▼ 1.8%
7d—
14d—
30d—
1y—
🏦Market Cap
$6M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
52
Weak
No chart data available for LABT.
Trading Snapshot
- Day Range
- $885.16 – $906.49
- 52-Week Range
- $0.37 – $9.82
- Volume
- $3.92B
- Avg Volume
- $3.94B
- Shares Outstanding
- 1.8M
- Next Earnings
- Oct 4, 2026
Fundamentals Snapshot
- Annual Revenue
- $726,294
- Last Q Revenue
- $200,033
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- —
- Dividend Yield
- —
Why Investors Own LABT
- ✓High-growth profile — revenue up +46.3% YoY with expanding US Equity exposure.
- ✓Healthy economics — 58% gross margin and 4% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$726,294▲ +51.8% YoY
Gross Margin (TTM)
58.3%▲ +2.8% YoY
Operating Income (TTM)
$228,783▲ +51.8% YoY
Free Cash Flow (TTM)
$30,504▲ +51.8% YoY
About LAKEWOOD-AMEDEX BIOTHERAPEUT
A company profile for LAKEWOOD-AMEDEX BIOTHERAPEUT isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
52/100
Analyst Price Target
ⓘAverage Target
$1,048.01
▲ +17.3% Upside
High Target$1,204.95
Low Target$793.94
Based on 24 analysts
Latest News & Updates
🚀
Barron’s·2h ago
LAKEWOOD-AMEDEX BIOTHERAPEUT tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
MarketWatch·5h ago
Analysts lift LABT price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Bloomberg·1d ago
LAKEWOOD-AMEDEX BIOTHERAPEUT announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.